INHIBRX BIOSCIENCES, INC. Earnings Per Share (Basic)
INHIBRX BIOSCIENCES, INC. (INBX) reported Earnings Per Share (Basic) of -$2.34 per share for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasic · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2026-06-30 was -$2.34.
- INHIBRX BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2026-03-31 was -$2.15.
- INHIBRX BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2025-12-31 was -$2.11.
- INHIBRX BIOSCIENCES, INC. earnings per share, basic for the quarter ending 2025-09-30 was -$2.28.
- INHIBRX BIOSCIENCES, INC. earnings per share, basic for fiscal 2025 was -$9.04, a 107.93% decline from fiscal 2024.
- INHIBRX BIOSCIENCES, INC. earnings per share, basic for fiscal 2024 was $114.01.
- INHIBRX BIOSCIENCES, INC. earnings per share, basic for fiscal 2023 was -$20.48.
| Period end | Earnings Per Share, Basic 3 month | Earnings Per Share, Basic 6 month | Earnings Per Share, Basic 9 month | Earnings Per Share, Basic 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$2.34 10-Q · filed 2026-08-13 | -$4.49 10-Q · filed 2026-08-13 | -$6.60 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$8.88 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2026-03-31 | -$2.15 10-Q · filed 2026-05-14 | -$4.26 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$6.54 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$8.39 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-12-31 | -$2.11 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$4.39 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$6.24 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$9.04 10-K · filed 2026-03-19 |
| 2025-09-30 | -$2.28 10-Q · filed 2025-11-14 | -$4.13 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$6.93 10-Q · filed 2025-11-14 | -$10.02 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-06-30 | -$1.85 10-Q · filed 2026-08-13 | -$4.65 10-Q · filed 2026-08-13 | -$7.75 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$10.58 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2025-03-31 | -$2.80 10-Q · filed 2026-05-14 | -$5.89 derived: net income ÷ weighted average shares · filed 2026-08-13 | -$8.73 derived: net income ÷ weighted average shares · filed 2026-08-13 | $112.93 derived: net income ÷ weighted average shares · filed 2026-08-13 |
| 2024-12-31 | -$3.09 derived: net income ÷ weighted average shares · filed 2026-03-19 | -$5.93 derived: net income ÷ weighted average shares · filed 2026-03-19 | $116.30 derived: net income ÷ weighted average shares · filed 2026-03-19 | $114.01 10-K · filed 2026-03-19 |
| 2024-09-30 | -$2.84 10-Q · filed 2025-11-14 | $120.59 derived: net income ÷ weighted average shares · filed 2025-11-14 | $119.04 10-Q · filed 2025-11-14 | $114.70 derived: net income ÷ weighted average shares · filed 2025-11-14 |
| 2024-06-30 | $127.10 10-Q · filed 2025-08-13 | $125.93 10-Q · filed 2025-08-13 | $121.02 derived: net income ÷ weighted average shares · filed 2025-11-14 | $121.99 derived: net income ÷ weighted average shares · filed 2025-11-14 |
| 2024-03-31 | -$5.77 10-Q · filed 2025-05-14 | -$12.69 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$17.26 derived: net income ÷ weighted average shares · filed 2025-11-14 | -$21.75 derived: net income ÷ weighted average shares · filed 2025-11-14 |
| 2023-12-31 | -$6.92 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$11.49 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$15.94 derived: net income ÷ weighted average shares · filed 2025-03-17 | -$20.48 10-K · filed 2025-03-17 |
| 2023-09-30 | -$4.39 10-Q · filed 2024-11-14 | -$8.71 derived: net income ÷ weighted average shares · filed 2024-11-14 | -$13.19 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$4.31 10-Q · filed 2024-08-13 | -$8.80 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |